Cagrilintide

Cagrilintide is presented here as a laboratory catalogue entry for research environments that need clear identification, labelled variants, and direct access to supporting records. The current listing includes 2 labelled variants: 5mg and 10mg. That structure keeps the page useful as both a procurement reference and an indexable resource covering stock visibility, pricing context, and documentation.

Within the wider Au Peptide Labs catalogue, Cagrilintide sits alongside Cagrilintide + Semaglutide, Retatrutide, and Tesamorelin. Researchers often review neighbouring compounds before selecting a comparator or deciding which sequence belongs in a screening panel. Keeping those internal paths close to the product page improves traceability and helps laboratory buyers compare materials without relying on vague or consumer-style copy.

In research literature, Cagrilintide is generally treated as a long-acting amylin receptor analog structurally derived from human amylin (IAPP), with proline substitutions at positions 25 and 28 and a C18 fatty acid chain to prevent β-sheet aggregation and extend circulating half-life. Amylin receptors are obligate heterodimers of the calcitonin receptor (CTR) with one of three receptor activity-modifying proteins (RAMP1-3), generating AMY1, AMY2, and AMY3 subtypes with distinct ligand preferences. Cagrilintide binding triggers Gs-mediated cAMP accumulation and, depending on receptor subtype, Gq-linked IP3/DAG signalling, making subtype selectivity a relevant experimental variable. Wild-type human amylin (hIAPP) fibrillises rapidly in vitro at physiological concentrations — the proline substitutions in cagrilintide prevent β-sheet nucleation, providing a stable monomeric comparator for aggregation kinetics studies.

Research panels frequently pair cagrilintide with GLP-1R agonists to examine whether AMY receptor co-stimulation modifies incretin-pathway outputs. Its stability advantage over native IAPP also makes it useful as a non-aggregating amylin reference in fibrillation inhibition screens. For laboratory teams, the practical emphasis is usually on sequence identity, receptor or pathway relevance where documented, and whether Cagrilintide behaves consistently across stability, purity, and analytical verification workflows. Variant labels on this page support clearer internal referencing when multiple labelled variants are under review.

If a product-specific file is not attached to this listing, the wider COA library remains the correct reference point for current published documentation. The COA section is useful for confirming how the product is labelled in the catalogue, whether purity information has been published, and whether the laboratory record for the material is complete before bench use.

When teams compare Cagrilintide with Cagrilintide + Semaglutide, Retatrutide, and Tesamorelin, COA access also helps keep comparator decisions grounded in documented material identity rather than assumption. That is especially important for research pages that combine pricing, variant selection, and analytical records on a single URL.